Skip to main
  1. Stocks
  2. Eupraxia Pharmaceuticals Inc
  3. Forecast
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals is positioned for upside because its DiffuSphere platform has already shown durable, localized drug delivery across two tissue environments, while EP-104GI’s open-label data suggest ~80% clinical remission at 6 months, 64% remission at 52 weeks in evaluable patients, and a clean safety profile with zero candidiasis, zero adrenal suppression, and no serious drug-related adverse events across 275+ patient-months. The upcoming December randomized Phase 2b RESOLVE interim readout is the key near-term catalyst, especially because the company has completed enrollment of 120 patients and ended 3Q26 with $126.4M in cash and short-term investments, providing runway into 2H28. Fundamentally, the stock appeal rests on a large, undertreated EoE market, differentiated once-yearly dosing, and a commercial model that could be supported by strong physician interest, practical endoscopy workflow fit, and meaningful reimbursement economics.

Bears say

Eupraxia Pharmaceuticals is a clinical-stage, pre-revenue biotech with no approved products, no revenue, and an accumulated deficit of $196.7MM as of June 30, 2026, so its valuation depends almost entirely on uncertain clinical success. Its lead program, EP-104GI, faces a high-stakes first vehicle-controlled readout after only open-label data from n=31, while management expects at least one Phase 3 study and further capital to be required, creating meaningful dilution risk. Commercially, the company is boxed in by powerful competition from dupilumab and tezepelumab, a $6,200 to $109,000 EoE pricing spectrum, endoscopy-based adoption barriers, and license economics that include up to 4% royalties and 20% of monetization proceeds at the current stage.

EPRX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

EPRX Analyst Forecast & Price Prediction

Get the latest EPRX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in EPRX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 6 analysts, EPRX has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


EPRX Analyst Forecast & Price Prediction

Get the latest EPRX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in EPRX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EPRX stock data and trends